Please note, this OEL/ADE monograph also applies to flurbiprofen sodium (CAS RN 56767-76-1) and flurbiprofen axetil (CAS RN 91503-79-6). Flurbiprofen is indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis and osteoarthritis, for ankylosing spondylitis, to treat pain associated with dysmenorrhea, and to treat mild to moderate pain cause by inflammation (bursitis, tendonitis, soft tissue trauma). Similar to other NSAIDs, the mechanism of action is not known exactly. The antiinflammatory effect involves inhibition of cyclooxygenase (non-selectively inhibits both COX-1 and COX-2).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Flurbiprofen, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.